AG
NBIX icon

Aperio Group’s Neurocrine Biosciences NBIX Stock Holding History

Aperio Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.35M Buy
34,936
+348
+1% +$33.6K 0.01% 1006
2020
Q3 		$3.33M Sell
34,588
-716
-2% -$82.8K 0.01% 891
2020
Q2 		$4.31M Buy
35,304
+1,285
+4% +$142K 0.02% 777
2020
Q1 		$2.94M Sell
34,019
-2,228
-6% -$218K 0.01% 853
2019
Q4 		$3.9M Buy
36,247
+2,557
+8% +$268K 0.01% 835
2019
Q3 		$3.04M Sell
33,690
-52
-0.2% -$4.86K 0.01% 884
2019
Q2 		$2.85M Buy
33,742
+5,642
+20% +$463K 0.01% 913
2019
Q1 		$2.48M Buy
28,100
+244
+0.9% +$20.4K 0.01% 954
2018
Q4 		$1.99M Sell
27,856
-2,715
-9% -$260K 0.01% 990
2018
Q3 		$3.76M Buy
30,571
+1,866
+7% +$212K 0.02% 781
2018
Q2 		$2.82M Buy
28,705
+1,658
+6% +$148K 0.01% 865
2018
Q1 		$2.24M Buy
27,047
+2,080
+8% +$176K 0.01% 942
2017
Q4 		$1.94M Buy
24,967
+3,055
+14% +$208K 0.01% 994
2017
Q3 		$1.34M Sell
21,912
-412
-2% -$21.7K 0.01% 1119
2017
Q2 		$1.03M Buy
22,324
+789
+4% +$38.3K 0.01% 1227
2017
Q1 		$932K Sell
21,535
-2,479
-10% -$106K 0.01% 1204
2016
Q4 		$929K Buy
24,014
+5,200
+28% +$235K 0.01% 1167
2016
Q3 		$953K Buy
18,814
+7,294
+63% +$363K 0.01% 1126
2016
Q2 		$523K Buy
11,520
+2,114
+22% +$97.3K ﹤0.01% 1359
2016
Q1 		$372K Buy
9,406
+1,761
+23% +$69.9K ﹤0.01% 1522
2015
Q4 		$432K Buy
7,645
+901
+13% +$45.8K ﹤0.01% 1416
2015
Q3 		$268K Buy
6,744
+760
+13% +$36.7K ﹤0.01% 1620
2015
Q2 		$286K Buy
5,984
+654
+12% +$27.7K ﹤0.01% 1667
2015
Q1 		$212K Buy
+5,330
New +$191K ﹤0.01% 1798

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aperio Group's NBIX Position: Q4 2020 in Review

Aperio Group increased its Neurocrine Biosciences (NBIX) stake by 1% in Q4 2020, buying an estimated $33.6K and bringing the position to 34,936 shares worth $3.35M. The position accounts for 0.01% of the portfolio, ranked #1006.

Aperio Group first reported a position in NBIX in Q1 2015 and has held it in 24 quarters since. The position peaked at $4.31M in Q2 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • Aperio Group held 34,936 shares of Neurocrine Biosciences worth $3.35M as of Q4 2020.
  • Aperio Group bought 348 Neurocrine Biosciences shares in Q4 2020, an estimated $33.6K.
  • Neurocrine Biosciences made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1006 holding.
  • Aperio Group first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 24 quarters since.
  • Aperio Group's Neurocrine Biosciences position peaked at $4.31M in Q2 2020.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.